Lipid profiles and hypertriglyceridemia among transgender and gender diverse adults on gender-affirming hormone therapy

Gender-affirming hormone therapy (GAHT) is common among transgender and gender-diverse adults. Transmasculine adults typically receive testosterone and transfeminine adults generally receive a combination of estrogen and an antiandrogen if they have not undergone an orchiectomy. GAHT is medically-necessary treatment taken to align physical characteristics with gender identity and to improve quality of life and psychological well-being1,2. Nonetheless, GAHT has important metabolic effects that likely alter cardiovascular risk.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Original Research Source Type: research